MedTrace Logo

Rivaroxaban Post Coronary Bypass Surgery

NCT06019741 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2023-09-06

No results posted yet for this study

Summary

Post coronary bypass patients were randomized to receiving aspirin alone or aspirin and low dose rivaroxaban

Conditions

  • Post Coronary Bypass Surgery Patients

Interventions

DRUG

Rivaroxaban and aspirin 80

rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery

DRUG

Aspirin 80

aspirin 80 mg orally post coronary bypass surgery

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-05-01
Completion
2022-07-20

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06019741 on ClinicalTrials.gov